Trial reportJournal of neural transmission (Vienna, Austria : 1996)2006
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 246 citations in OpenAlex.
- Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Dystonia rating scales: critique and recommendations.Movement disorders : official journal of the Movement Disorder Society · 2013Pooled it
- Pooled it
- Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Blepharospasm: A Multicenter, Phase 3 Study in Japan.Toxins · 2026Trial
- A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.BMC neurology · 2022Trial
- Trial
- Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.Korean journal of ophthalmology : KJO · 2019Trial
- IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study.Advances in therapy · 2019Trial
- Trial
- Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity.Muscle & nerve · 2016Trial
- Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.Journal of neurology, neurosurgery, and psychiatry · 2013Trial
- Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.Journal of neural transmission (Vienna, Austria : 1996) · 2013Trial
- Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.Journal of neural transmission (Vienna, Austria : 1996) · 2013Trial
- [Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2011Trial
- Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.Journal of neural transmission (Vienna, Austria : 1996) · 2011Trial
- [Does dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella lines].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2009Trial
- Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.Korean journal of ophthalmology : KJO · 2009Trial
- Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis.Neurology and therapy · 2026Article
- Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity.Toxins · 2025Article
- Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin.Acta neurologica Belgica · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial, we compared the efficacy and safety of NT 201 and BOTOX in patients suffering from blepharospasm. Of 304 enrolled patients, 300 patients received study medication (intent-to-treat population), and 256 patients completed the study as planned (per-protocol population). At baseline, patients received a single injection of NT 201 or BOTOX (<or=35 units per eye). No significant differences were found between NT 201 and BOTOX for all efficacy and safety variables three weeks after injection. Both the NT 201 and the BOTOX group showed a decrease in the Jankovic Rating Scale (JRS) sum score signifying an improvement in the symptoms of blepharospasm during this time period. These data show that NT 201* is an effective and safe treatment for patients suffering from blepharospasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.